Table 1.
Summary of the specificities and clinical trials of HDAC inhibitors in GVHD.
| Name | Classification | HDAC specificity | Clinical research stage in GVHD | For GVHD |
|---|---|---|---|---|
| SAHA | Hydroxamic acids SCFAs | Pan-HDACi | I/II (16, 17) | Prophylaxis |
| Panobinostat | Pan-HDACi | I/II1, 2 | Treatment | |
| Butyrate | SCFAs | Pan-HDACi | II (18)3 | Prophylaxis |
| Romidepsin | Cyclic peptides | Class I and II HDACs (mainly HDAC1 and 2) | I4 | Prophylaxis |
| Chidamide | Benzamides | Pan-HDACi | Not reported yet | |
| Nicotinamide | SIRT inhibitors | Class III HDACs | I/II (19) | Prophylaxis |